Several studies have investigated the feasibility and usefulness of an 89Zr radiolabeled compound with J591 monoclonal antibody (mAb)—known to bind the PSMA extracellular domain—in identifying tumor foci [103,104,149,150,151]. This evidence concerns the gene FOLH1 and neoplasm.